IN2014DN01883A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN01883A IN2014DN01883A IN1883DEN2014A IN2014DN01883A IN 2014DN01883 A IN2014DN01883 A IN 2014DN01883A IN 1883DEN2014 A IN1883DEN2014 A IN 1883DEN2014A IN 2014DN01883 A IN2014DN01883 A IN 2014DN01883A
- Authority
- IN
- India
- Prior art keywords
- pyridin
- chlorophenyl
- pyrazolo
- pyrrolo
- piperidin
- Prior art date
Links
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 18
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 6
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 abstract 3
- 229940113083 morpholine Drugs 0.000 abstract 3
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 abstract 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 abstract 2
- QATYRYIZQCZJPK-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-piperidin-4-ylpyrrolo[2,3-c]pyridin-4-ol Chemical compound C1=2C(O)=CN=CC=2N(C=2C=CC(Cl)=CC=2)C=C1C1CCNCC1 QATYRYIZQCZJPK-UHFFFAOYSA-N 0.000 abstract 1
- YZXLJBAURSYRBM-UHFFFAOYSA-N 5-amino-1-[4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]pentan-1-one Chemical compound C1CN(C(=O)CCCCN)CCC1C(C1=CC=NC=C11)=CN1C1=CC=C(Cl)C=C1 YZXLJBAURSYRBM-UHFFFAOYSA-N 0.000 abstract 1
- 102100027159 Membrane primary amine oxidase Human genes 0.000 abstract 1
- 101710132836 Membrane primary amine oxidase Proteins 0.000 abstract 1
- KRGICSYONBDZHH-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(N2C(CCCC2)C(=O)N2CCNCC2)=N1 KRGICSYONBDZHH-UHFFFAOYSA-N 0.000 abstract 1
- NMUZEXQMQNXYNZ-UHFFFAOYSA-N [4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC2)C(=O)N2CCNCC2)=C1 NMUZEXQMQNXYNZ-UHFFFAOYSA-N 0.000 abstract 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 abstract 1
- YPSPPJRTCRMQGD-UHFFFAOYSA-N morpholine-3-carboxamide Chemical compound NC(=O)C1COCCN1 YPSPPJRTCRMQGD-UHFFFAOYSA-N 0.000 abstract 1
- NYDFDDONODKIFA-UHFFFAOYSA-N n-(2-aminoethyl)-1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidine-2-carboxamide Chemical compound NCCNC(=O)C1CCCCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 NYDFDDONODKIFA-UHFFFAOYSA-N 0.000 abstract 1
- NQEUXJIRFMCWBP-UHFFFAOYSA-N n-(2-aminoethyl)-1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)NCCN)CCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 NQEUXJIRFMCWBP-UHFFFAOYSA-N 0.000 abstract 1
- QILNKYDVBQWLTA-UHFFFAOYSA-N n-butyl-1-(4-chlorophenyl)-n-methylpyrazolo[3,4-c]pyridin-3-amine Chemical compound C12=CN=CC=C2C(N(C)CCCC)=NN1C1=CC=C(Cl)C=C1 QILNKYDVBQWLTA-UHFFFAOYSA-N 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
Abstract
2-{4-[l-(4-chlorophenyl)-lH-pyrrolo[2,3-c]pyridin-3-yl]piperidin-l-yl}ethan-l-amine; 3- aminopropyl 4-[l-(4- chlorophenyl)-lH-pyrrolo[2,3-c]pyridin-3-yl]piperidine-l-carboxylate; l-{4-[l -(4-chlorophenyl)-lH-pyrrolo[2,3-c]pyridin-3- yl]piperidin- 1-yl} -4- (dimethylamino)butan- 1-one; 5-amino- 1- {4-[ 1-(4-chlorophenyl)- lH-pyrrolo[2,3-c]pyridin-3- yl]piperidin- 1- yl}pentan- 1-one; N-(2-aminoethyl)-4-[l -(4-chlorophenyl)- lH-pyrrolo[2,3- c]pyridin-3-yl]piperidine- 1-carboxamide; N-(3-aminop - ropyl)-4-[l-(4-chlorophenyl)-lH- pyrrolo[2,3-c]pyridin-3-yl]piperidine-l -carboxamide; 4-[l -(4-chlorophenyl)- lH-pyrrolo[2, 3- c]pyridin-3-yl]-N-[3-(dimethylamino)propyl]piperidine- 1-carboxamide; 1-({4-[ 1-(4- chlorophenyl)- lH-pyrrolo[2,3-c]pyridin-3- yl]piperidin- 1-yl} carbonyl)piperazine; 4-( {4-[ 1-(4- chlorophenyl)- lH-pyrrolo[2,3-c]pyridin-3-yl]piperidin- 1-yl} carbonyl)mor - pholine; l-({4-[l-(4- chlorophenyl)-lH-pyrrolo[2,3-c]pyridin-3-yl]piperidin-l-yl}carbonyl)-l,4-diazepane; ethyl 1- [l-(4- chlorophenyl)-lH-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylate; ethyl l-[l-(4- methylphenyl)-lH-pyrazolo[3,4-c]pyridin-3- yl]piperidine-4-carboxylate; l-[l-(4- chlorophenyl)-lH-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid; N-(2- aminoethyl)- 1-[1 -(4-chlorophenyl)- lH-pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxamide; 4-({ l-[ 1-(4-chlorophenyl)- 1Hpyrazolo[ 3,4-c]pyridin-3-yl]piperidin-4 yl}carbonyl)morpholine; 1-({ 1-[1-(4-chlorophenyl)- lH-pyrazolo[3,4-c]pyridin-3-yl]piperid - in- 4-yl}carbonyl)piperazine; {4-[l -(4-methylphenyl)-lH-pyrazolo[3,4-c]pyridin-3-yl]morpholin- 3-yl}methanol; {4-[l-(4-methylphenyl)-lH-pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl}methanol; [(3R)-4-[l -(4-chlorophenyl)- lH-pyrazolo[3,4-c]pyridin-3- yl]morpholin-3- yl]methanol; methyl 4-[l -(4-chlorophenyl)-lH-pyrazolo[3,4-c]pyridin-3-yl]morpholine-3- carboxylate; N-(2- aminoethyl)-4-[l -(4-chlorophenyl)- lH-pyrazolo[3,4-c]pyridin-3- yl]morpholine-3-carboxamide; 2-{4-[l-(4-chlorophenyl)-lHpyrazolo[ 3,4-c]pyridin-3- yl]morpholin-3-yl}ethan-l-ol; methyl l-[l-(4-chlorophenyl)-lH-pyrazolo[3,4-c]pyridin-3- yljpiperidine 2-carboxylate; N-(2-aminoethyl)- 1-[1-(4-chlorophenyl)- lH-pyrazolo[3,4- c]pyridin-3-yl]piperidine-2-carboxamide; 1-({ 1-[1 -(4- chlorophenyl)-lH-pyrazolo[3,4- c]pyridin-3-yl]piperidin-2-yl}carbonyl)piperazine; 4-[l-(4-methylphenyl)-lH-pyrrolo[2,3- c]pyrid- in-3-yl]morpholine; 1-(4-chlorophenyl)-3-(piperidin-4-yl)- lH-pyrrolo[2,3-c]pyridin-4- ol; N-butyl- 1-(4-chlorophenyl)-N-methyllH- pyrazolo[3,4-c]pyridin-3-amine; l-[4- (fluoromethyl)phenyl]-3-(oxan-4-yl)-lH-pyrazolo[3,4-c]pyridine; and 3-({4-[l-(4- chlorophenyl)-lH-pyrazolo[3,4-c]pyridm-3-yl]piperidin-l-yl}methyl)pyridine are useful for the inhibition of SSAO activity.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/065967 WO2013037411A1 (en) | 2011-09-14 | 2011-09-14 | New enzyme inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN01883A true IN2014DN01883A (en) | 2015-05-15 |
Family
ID=44677871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1883DEN2014 IN2014DN01883A (en) | 2011-09-14 | 2011-09-14 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9150574B2 (en) |
| EP (1) | EP2755974A1 (en) |
| JP (1) | JP5796130B2 (en) |
| CN (1) | CN103889983B (en) |
| AU (1) | AU2011376717A1 (en) |
| BR (1) | BR112014005793A2 (en) |
| CA (1) | CA2847193A1 (en) |
| EA (1) | EA201490451A1 (en) |
| IL (1) | IL231353A0 (en) |
| IN (1) | IN2014DN01883A (en) |
| SG (1) | SG11201400277VA (en) |
| WO (1) | WO2013037411A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| GB201416446D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| JP2019502672A (en) | 2015-12-07 | 2019-01-31 | ベネボレンタイ ケンブリッジ リミティド | VAP-1 inhibitor for the treatment of pain |
| MA47203A (en) * | 2017-01-09 | 2019-11-13 | Ardelyx Inc | NHE-MEDIATION ANTIPORT INHIBITORS |
| EP3843846A4 (en) * | 2018-08-27 | 2022-09-07 | Spinogenix, Inc. | FASCIN-BINDING COMPOUNDS FOR SPINOGENESIS |
| JP2022534914A (en) | 2019-05-29 | 2022-08-04 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | microbicidal derivatives |
| EP4136076A1 (en) * | 2020-04-16 | 2023-02-22 | F. Hoffmann-La Roche AG | Biphenyl derivatives |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES |
| WO2023193790A1 (en) * | 2022-04-08 | 2023-10-12 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| DE19649460A1 (en) | 1996-11-26 | 1998-05-28 | Bayer Ag | New substituted pyrazole derivatives |
| DE60004543T2 (en) | 1999-09-14 | 2004-06-17 | Aventis Pharmaceuticals Inc. | BENZISOXAZOLYL, PYRIDOISOXAZOLYL AND BENZTHIENYL PHENOXY DERIVATIVES AS D4 ANTAGONISTS |
| WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
| US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| DE60228103D1 (en) | 2001-10-02 | 2008-09-18 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| US7456169B2 (en) | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
| KR20060073929A (en) | 2003-08-08 | 2006-06-29 | 라 졸라 파마슈티칼 컴파니 | Inhibitors of semicarbazide sensitive amineoxidase (SASO) and BAP-1 mediated adhesions useful for treating diseases |
| JP5069907B2 (en) | 2003-09-17 | 2012-11-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Fused heterocyclic compounds |
| EP1730148A4 (en) | 2004-02-03 | 2009-08-19 | Abbott Lab | Aminobenzoxazoles as therapeutic agents |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| CA2605738C (en) | 2005-04-25 | 2013-10-01 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Novel azaheterocyclic compounds as kinase inhibitors |
| KR20140026644A (en) | 2005-06-22 | 2014-03-05 | 케모센트릭스, 인크. | Azaindazole compounds and methods of use |
| WO2007120528A2 (en) | 2006-03-31 | 2007-10-25 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
| BRPI0710527B8 (en) | 2006-04-04 | 2021-05-25 | Fibrogen Inc | pyrrolo- and thiazolo-pyridine compounds and pharmaceutical composition comprising them |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| WO2008088744A1 (en) | 2007-01-17 | 2008-07-24 | Merck & Co., Inc. | Decahydroquinoline analogs as cb2 receptor modulators |
| CA2683821A1 (en) | 2007-05-02 | 2008-11-13 | Novartis Ag | Heterocyclic compounds and their use as pesticides |
| GB0725103D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| KR101577943B1 (en) | 2008-01-31 | 2015-12-16 | 사노피 | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| WO2009108551A2 (en) * | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| BRPI0918602B8 (en) | 2008-09-16 | 2021-05-25 | Benevolentai Cambridge Ltd | health activity inhibitors, their use, and pharmaceutical formulation |
| JP5613671B2 (en) * | 2008-09-16 | 2014-10-29 | プロキシマジェン エルティーディーＰｒｏｘｉｍａｇｅｎ Ｌｔｄ． | Novel compound II |
| WO2010064020A1 (en) * | 2008-12-04 | 2010-06-10 | Proximagen Ltd. | Imidazopyridine compounds |
| JP2012211085A (en) | 2009-08-12 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | Hedgehog signal inhibitor |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
-
2011
- 2011-09-14 EP EP11761040.2A patent/EP2755974A1/en not_active Withdrawn
- 2011-09-14 IN IN1883DEN2014 patent/IN2014DN01883A/en unknown
- 2011-09-14 SG SG11201400277VA patent/SG11201400277VA/en unknown
- 2011-09-14 CA CA2847193A patent/CA2847193A1/en not_active Abandoned
- 2011-09-14 WO PCT/EP2011/065967 patent/WO2013037411A1/en active Application Filing
- 2011-09-14 JP JP2014530103A patent/JP5796130B2/en not_active Expired - Fee Related
- 2011-09-14 BR BR112014005793A patent/BR112014005793A2/en not_active IP Right Cessation
- 2011-09-14 AU AU2011376717A patent/AU2011376717A1/en not_active Abandoned
- 2011-09-14 CN CN201180073402.9A patent/CN103889983B/en not_active Expired - Fee Related
- 2011-09-14 US US14/344,417 patent/US9150574B2/en not_active Expired - Fee Related
- 2011-09-14 EA EA201490451A patent/EA201490451A1/en unknown
-
2014
- 2014-03-06 IL IL231353A patent/IL231353A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9150574B2 (en) | 2015-10-06 |
| WO2013037411A1 (en) | 2013-03-21 |
| JP2015502913A (en) | 2015-01-29 |
| CN103889983A (en) | 2014-06-25 |
| EA201490451A1 (en) | 2014-12-30 |
| AU2011376717A1 (en) | 2014-03-20 |
| SG11201400277VA (en) | 2014-05-29 |
| CN103889983B (en) | 2015-12-09 |
| US20140357623A1 (en) | 2014-12-04 |
| BR112014005793A2 (en) | 2017-03-28 |
| CA2847193A1 (en) | 2013-03-21 |
| EP2755974A1 (en) | 2014-07-23 |
| IL231353A0 (en) | 2014-04-30 |
| JP5796130B2 (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN01883A (en) | ||
| US11168090B2 (en) | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | |
| PH12013501837A1 (en) | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases | |
| JP2012508776A5 (en) | ||
| JP2015510938A5 (en) | ||
| JP6997876B2 (en) | Substituted pyrazolyl [4,3-C] pyridine compound as a RET kinase inhibitor | |
| RU2012113593A (en) | JAK INHIBITORS | |
| NO20061528L (en) | Polymrophic forms of 3- (4-amino-1-oxo-1,3 dihydro-isoindol-2-yl) -piperidine-2,6-dione | |
| SI2046331T1 (en) | Use of 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment of mantle cell lymphomas | |
| JP2006503866A5 (en) | ||
| JP2017501981A5 (en) | ||
| UA94928C2 (en) | Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine | |
| ZA201000212B (en) | Fused heteroaryl pyridyl and phenyl benzenesulfonamides as ccr2 modulators for the treatment of inflammation | |
| HRP20120240T1 (en) | PIRIDIL PIPERIDIN ORREXIN ANTAGONIST RECEPTORA | |
| CL2008002717A1 (en) | 3- (1-chlorophenyl) -7-oxo-6- [4- (2-oxo-1 (2h) pyridinyl) phenyl] -4,5,6,7-tetrahydro-1h-pyrazolo [3,4-c ] pyridine-3-carboxamide and 3- (1-hydroxy-1-methyl-ethyl) -1- (a-methoxy-phenyl) -6- [4- (2-oxo-2h-pyridin-1-yl) - phenyl] -1,4,5,6-tetrahydro-pyrazolo [3,4-c] pyridin-7-one; pharmaceutical composition; Pharmaceutical combination and use in the treatment of a thromboembolic disorder | |
| JP2016519096A5 (en) | ||
| NZ594765A (en) | Anthelmintic agents and their use | |
| JP2013526536A5 (en) | ||
| WO2005095379A3 (en) | Crystalline methanesulfonic acid addition salts of imatinib | |
| ATE462701T1 (en) | METHOD FOR PRODUCING 4-(PHENOXY-5-METHYL-PYRIMIDINE-4-YLOXY)PIPERIDINE 1-CARBOXYLIC ACID DERIVATIVES AND RELATED COMPOUNDS | |
| PT2358674E (en) | Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | |
| ZA201500462B (en) | Method for producing 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridine-2-carbonitrile, and intermediate thereof | |
| JP2019520412A5 (en) | ||
| ZA201207483B (en) | Method of preparing (+)-1,4-dihydro-7-(3s-4s)-3methoxy-4-methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazoly)-1,8-naphthyridine-3-carboxylic acid | |
| AU2010224865A1 (en) | Piperidine derivatives as NK3 receptor antagonists |